SOPH Stock Forecast & Price Target

Sophia Genetics is a fast-growing healthcare technology company with a global presence and strong revenue growth. With a focus on longitudinal patient data and partnerships with big players like AstraZeneca, SOPHiA is expected to see continued growth and profitability in the medium term. However, the company's current lack of profitability and potential for continued losses may be a concern for some investors.

Sophia Genetics is a healthcare technology company with a promising land and expand model, but its financials and potential future revenue are concerning. Although the company has seen an increase in average contract value and has signed major deals with integrated health systems, their revenue estimates are still low and their share price is overvalued. Additionally, while their partnerships with biopharma companies like AstraZeneca may provide some stability, there are no guarantees for future extensions or deals. These risks, combined with a lack of quantified information on key deals, contribute to a negative outlook on Sophia Genetics's stock.